A Clinical Trial of Multiple Doses of GR2301 Injection in Healthy Adult Trial Participants in China.
Condition(s) studied
Investigational drug(s) / intervention(s)
GR2301 injection: IL15 monoclonal antibody
Study summary
This is a randomized, double-blind, placebo-controlled Phase I clinical trial evaluating the safety, tolerability, pharmacokinetics and immunogenicity characteristics of GR2301 injection in healthy adult subjects in China. The Multiple doses will be gradually escalated.
Eligibility
Primary outcome measure(s)
- Adverse events (AEs) — Up to 52 Weeks
Incidence of AEs
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Beijing Tongren Hospital Affiliated to Capital Medical University | Beijing | Beijing Municipality |
More Genrix (Shanghai) Biopharmaceutical Co., Ltd. trials in China
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07647224 on ClinicalTrials.gov ↗ ← All trials in China